XML 78 R68.htm IDEA: XBRL DOCUMENT
v3.22.2

Segment Reporting - Sales from Products (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021
Segment Reporting Information [Line Items] |  |  |  |
Sales | $ 14,593 | $ 11,402 | $ 30,494 | $ 22,029
Revenue related to the sale of the marketing rights |  |  | 146 | 56
U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 6,238 | 5,100 | 13,577 | 9,890
Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 8,355 | 6,301 | 16,917 | 12,139
Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 14,223 | 11,452 | 29,812 | 22,108
Operating Segments | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 6,203 | 5,106 | 13,449 | 9,837
Operating Segments | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 8,020 | 6,345 | 16,362 | 12,271
Corporate, Non-Segment |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 370 | (50) | 682 | (79)
Corporate, Non-Segment | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 35 | (6) | 128 | 53
Corporate, Non-Segment | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 335 | (44) | 555 | (132)
Pharmaceutical | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 12,756 | 9,980 | 26,863 | 19,218
Pharmaceutical | Operating Segments | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 5,726 | 4,647 | 12,498 | 8,941
Pharmaceutical | Operating Segments | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 7,030 | 5,333 | 14,364 | 10,277
Pharmaceutical | Operating Segments | Keytruda |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 5,252 | 4,176 | 10,061 | 8,076
Pharmaceutical | Operating Segments | Keytruda | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 3,197 | 2,347 | 5,976 | 4,528
Pharmaceutical | Operating Segments | Keytruda | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 2,055 | 1,829 | 4,085 | 3,548
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 275 | 248 | 541 | 475
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 143 | 124 | 283 | 242
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 132 | 124 | 257 | 233
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 231 | 181 | 459 | 310
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 128 | 88 | 284 | 173
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 103 | 93 | 175 | 137
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 33 | 0 | 86 | 0
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 28 | 0 | 55 | 0
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 5 | 0 | 30 | 0
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,674 | 1,234 | 3,133 | 2,151
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 428 | 454 | 846 | 766
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,245 | 781 | 2,287 | 1,385
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 578 | 516 | 1,047 | 965
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 434 | 386 | 805 | 718
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 143 | 130 | 243 | 246
Pharmaceutical | Operating Segments | RotaTeq |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 173 | 208 | 389 | 366
Pharmaceutical | Operating Segments | RotaTeq | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 98 | 111 | 273 | 229
Pharmaceutical | Operating Segments | RotaTeq | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 75 | 97 | 116 | 137
Pharmaceutical | Operating Segments | Pneumovax 23 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 153 | 152 | 325 | 323
Pharmaceutical | Operating Segments | Pneumovax 23 | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 94 | 100 | 212 | 173
Pharmaceutical | Operating Segments | Pneumovax 23 | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 59 | 52 | 114 | 150
Pharmaceutical | Operating Segments | Vaqta |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 35 | 56 | 71 | 90
Pharmaceutical | Operating Segments | Vaqta | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 16 | 22 | 45 | 47
Pharmaceutical | Operating Segments | Vaqta | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 19 | 34 | 25 | 43
Pharmaceutical | Operating Segments | Bridion |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 426 | 387 | 821 | 727
Pharmaceutical | Operating Segments | Bridion | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 237 | 197 | 432 | 364
Pharmaceutical | Operating Segments | Bridion | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 190 | 190 | 389 | 363
Pharmaceutical | Operating Segments | Prevymis |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 103 | 93 | 197 | 174
Pharmaceutical | Operating Segments | Prevymis | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 47 | 37 | 87 | 72
Pharmaceutical | Operating Segments | Prevymis | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 56 | 56 | 110 | 103
Pharmaceutical | Operating Segments | Primaxin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 64 | 60 | 122 | 125
Pharmaceutical | Operating Segments | Primaxin | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 1 | 0
Pharmaceutical | Operating Segments | Primaxin | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 64 | 60 | 122 | 125
Pharmaceutical | Operating Segments | Dificid |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 66 | 34 | 119 | 61
Pharmaceutical | Operating Segments | Dificid | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 63 | 32 | 113 | 56
Pharmaceutical | Operating Segments | Dificid | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 3 | 2 | 6 | 4
Pharmaceutical | Operating Segments | Noxafil |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 60 | 66 | 118 | 133
Pharmaceutical | Operating Segments | Noxafil | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 16 | 14 | 25 | 29
Pharmaceutical | Operating Segments | Noxafil | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 45 | 52 | 92 | 104
Pharmaceutical | Operating Segments | Invanz |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 46 | 48 | 99 | 104
Pharmaceutical | Operating Segments | Invanz | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 2 | (4) | 2 | 0
Pharmaceutical | Operating Segments | Invanz | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 45 | 52 | 96 | 104
Pharmaceutical | Operating Segments | Cancidas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 42 | 54 | 95 | 111
Pharmaceutical | Operating Segments | Cancidas | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 2 | 1 | 4 | 3
Pharmaceutical | Operating Segments | Cancidas | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 39 | 53 | 91 | 108
Pharmaceutical | Operating Segments | Zerbaxa |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 46 | (1) | 76 | (9)
Pharmaceutical | Operating Segments | Zerbaxa | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 22 | (2) | 40 | (4)
Pharmaceutical | Operating Segments | Zerbaxa | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 24 | 1 | 36 | (5)
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 98 | 74 | 170 | 149
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 88 | 81 | 159 | 149
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 10 | (7) | 11 | 0
Pharmaceutical | Operating Segments | Adempas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 63 | 74 | 124 | 129
Pharmaceutical | Operating Segments | Adempas | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Pharmaceutical | Operating Segments | Adempas | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 63 | 74 | 124 | 129
Pharmaceutical | Operating Segments | Lagevrio |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,177 | 0 | 4,424 | 0
Pharmaceutical | Operating Segments | Lagevrio | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 1,523 | 0
Pharmaceutical | Operating Segments | Lagevrio | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,177 | 0 | 2,901 | 0
Pharmaceutical | Operating Segments | Isentress/Isentress HD |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 147 | 192 | 305 | 401
Pharmaceutical | Operating Segments | Isentress/Isentress HD | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 67 | 74 | 128 | 145
Pharmaceutical | Operating Segments | Isentress/Isentress HD | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 80 | 118 | 177 | 256
Pharmaceutical | Operating Segments | Belsomra |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 69 | 78 | 137 | 157
Pharmaceutical | Operating Segments | Belsomra | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 19 | 14 | 39 | 32
Pharmaceutical | Operating Segments | Belsomra | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 50 | 63 | 98 | 125
Pharmaceutical | Operating Segments | Simponi |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 181 | 202 | 366 | 416
Pharmaceutical | Operating Segments | Simponi | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Pharmaceutical | Operating Segments | Simponi | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 181 | 202 | 366 | 416
Pharmaceutical | Operating Segments | Remicade |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 53 | 75 | 114 | 160
Pharmaceutical | Operating Segments | Remicade | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Pharmaceutical | Operating Segments | Remicade | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 53 | 75 | 114 | 160
Pharmaceutical | Operating Segments | Januvia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 756 | 784 | 1,535 | 1,593
Pharmaceutical | Operating Segments | Januvia | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 301 | 284 | 626 | 632
Pharmaceutical | Operating Segments | Januvia | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 455 | 500 | 909 | 961
Pharmaceutical | Operating Segments | Janumet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 476 | 477 | 931 | 962
Pharmaceutical | Operating Segments | Janumet | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 105 | 74 | 168 | 158
Pharmaceutical | Operating Segments | Janumet | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 371 | 403 | 762 | 805
Pharmaceutical | Operating Segments | Other pharmaceutical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 479 | 512 | 998 | 1,069
Pharmaceutical | Operating Segments | Other pharmaceutical | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 191 | 213 | 372 | 429
Pharmaceutical | Operating Segments | Other pharmaceutical | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 288 | 299 | 628 | 640
Animal Health | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,467 | 1,472 | 2,949 | 2,890
Animal Health | Operating Segments | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 477 | 459 | 951 | 896
Animal Health | Operating Segments | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 990 | 1,012 | 1,998 | 1,994
Animal Health | Operating Segments | Livestock |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 826 | 821 | 1,658 | 1,640
Animal Health | Operating Segments | Livestock | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 164 | 161 | 335 | 318
Animal Health | Operating Segments | Livestock | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 662 | 659 | 1,322 | 1,322
Animal Health | Operating Segments | Companion Animals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 641 | 651 | 1,291 | 1,250
Animal Health | Operating Segments | Companion Animals | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 313 | 298 | 616 | 578
Animal Health | Operating Segments | Companion Animals | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | $ 328 | $ 353 | $ 676 | $ 672

X
- Definition The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=mrk_InternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LenvimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AllianceRevenueReblozylMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VaqtaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrevymisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrimaxinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_DificidMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_InvanzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CancidasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZerbaxaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasVerquvoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LagevrioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BelsomraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LivestockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |